CNS Drugs

, Volume 7, Issue 2, pp 159–164

Levetiracetam

Adis New Drug Profile

DOI: 10.2165/00023210-199707020-00006

Cite this article as:
Haria, M. & Balfour, J.A. CNS Drugs (1997) 7: 159. doi:10.2165/00023210-199707020-00006

Summary

▲ Levetiracetam is an ethyl analogue of the nootropic agent piracetam.

▲ Results from rodent studies indicate that the drug may offer protection against absence, generalised and partial seizures.

▲ Levetiracetam exhibits linear pharmacokinetics and has a wide therapeutic index. Its potential to interact with other anticonvulsants appears to be low.

▲ Initial findings from a total of 29 patients with treatment-refractory epilepsy suggest that levetiracetam may be beneficial in patients with partial seizures. These results require confirmation.

▲ Somnolence and asthenia were the most common adverse events reported in patients receiving levetiracetam 1000 to 4000 mg/day; these appeared to be dose-related.

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations